David Bonderman, the colorful yet publicity-shy co-founder of Fort Worth-based private equity titan TPG Inc. who became a billionaire by spearheading ...
Shares of Gilead Sciences Inc. GILD inched 0.04% higher to $92.38 Wednesday, on what proved to be an all-around mixed trading session for the stock market, with the S&P 500 Index SPX rising 0.82% to 6 ...
The drug has been shown to be effective at preventing HIV infection but does not cure an existing HIV infection.
Gilead is going to start testing a drug it believes could prevent HIV infection with just a single shot every year.
Pharma company Gilead Sciences has been awarded a massive $31.8 million in damages in connection with a lawsuit claiming ...
Gilead Sciences’ top money maker Biktarvy has been the company’s crown jewel for years now, but with the HIV med inching ...
In a report released today, Michael Yee from Jefferies maintained a Buy rating on Gilead Sciences (GILD – Research Report), with a price target ...
Gilead Sciences (GILD – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Courtney ...
The work is a secondary analysis of the phase 3 Randomized Trial to Prevent Vascular Events in HIV (REPRIEVE), which demonstrated that the cholesterol-lowering medication pitavastatin reduced the risk ...
A drug used to treat HIV that has also shown promise in preventing infections is not a cure for those already infected, as ...
J&J aims to expand Darzalex's use even further in the blood cancer, while Merck & Co. and Novo Nordisk presented at ASH ...
A group of public health experts, social workers and advocates who work with people and communities affected by HIV in New Orleans gathered at CrescentCare’s St. Roch location on Thursday (Dec. 5) to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback